← Back to Clinical Trials
Recruiting NCT05046483

Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition ST-segment Elevation Myocardial Infarction (STEMI)
Sponsor German Diabetes Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2018-12-30
Completion 2028-12-30

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay between myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of STEMI people with diabetes mellitus to people with prediabetes and glucose tolerant people.

Eligibility Criteria

Inclusion Criteria: * Condition after new onset of ST-segment elevation myocardial infarction (STEMI) * Age 18-80 years * HbA1c \<9.0% * People with diagnosis of diabetes mellitus according to ADA and DDG criteria (i.e. HbA1c ≥6.5% and/or pathological oral glucose tolerance test) * Healthy people with normal glucose tolerance status according to ADA and DDG criteria (i.e. HbA1c \<5.7% and normal OGTT) * People with impaired glucose metabolism ("prediabetes") according to ADA and DDG criteria (i.e. impaired fasting glucose and/or impaired glucose tolerance and/or HbA1c 5.7-6.4%) * Consent-able, hemodynamically stable people, without sedation (e.g. opiates) or other interfering medication (e.g. catecholamines) Exclusion Criteria: * Diabetes mellitus category 3 A-H (ADA criteria), gestational diabetes * Current pregnancy * Infectious diseases, acute infections / fever * Immunosuppressive therapy * Severe chronic renal, liver or heart disease (e.g. serum creatinin ≥1.6 mg/dl, peripheral ar

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}